Clinical trials: SARS CoV 2 Virus
COVID-19
COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age
The primary objective of the study is to characterize the concentrations of casirivimab+imdevimab in serum over time after a single subcutaneous (SC) administration The secondary objectives of the study are: To assess the safety…
- Trial name
- NCT04992273
- Testing
- casirivimab+imdevimab
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Regeneron Pharmaceuticals
Severe Acute Respiratory Syndrome Coronavirus 2
Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients
This trial is designed to determine if the inflammation modulating effect of vagus nerve stimulation can improve pulmonary function and limit progression to ARDS in hospitalized COVID-19 hospitalized patients.
- Trial name
- NCT04379037
- Testing
- Transcutaneous Auricular Vagus Nerve Stimulation
- Where
- Argentina
- Volunteers
- 50 people
- Sponsor
- Nemechek Technologies
Respiratory Disease
QIAstat-Dx® Respiratory Panel Plus (RPP) Clinical Performance Study
This study will evaluate the clinical performance of the QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 target with a validated comparator method
- Trial name
- NCT05733559
- Testing
- QIAstat-Dx® Respiratory Panel Plus (RPP)
- Where
- United Kingdom
- Volunteers
- 565 people
- Sponsor
- QIAGEN Gaithersburg, Inc
SARS-CoV-2
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04470427
- Testing
- mRNA-1273
- Where
- 100 sites in United States
- Volunteers
- 30,415 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Covid 19, Influenza
Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza
2. Participants will: Take nitazoxanide 600mg (or placebo) orally twice daily for 7 days, for a total of 14 doses. Visit the clinic on the 7th day of treatment for a check-up and safety tests.
- Trial name
- NCT06817096
- Volunteers
- 340 people
- Sponsor
- Azidus Brasil
Coronavirus Infection COVID-19
Clinical Trial of a Medical Device "Device for Non-invasive Electromagnetic Therapy "TOR" in the Treatment of COVID-19"
A clinical trial was conducted with human participation in order to assess the safety and efficacy of the medical device "TOR device for non-invasive electromagnetic therapy" when used as an adjunct in combination with standard…
- Trial name
- NCT05220579
- Testing
- Exposure to "TOR" device, Exposure to switched off "TOR" device
- Where
- Russia
- Volunteers
- 236 people
- Sponsor
- Concern GRANIT
Post-Acute COVID-19 Syndrome
A Study of Apabetalone in Subjects With Long -COVID
This is an open label, multicentre, phase II clinical trial that aims to assess the efficacy and safety of oral Apabetalone with background dapagliflozin for up to 12 weeks in T2DM patients with a history of probable or confirmed…
- Trial name
- NCT06590324
- Testing
- Apabetalone
- Where
- 3 sites in Jordan, Saudi Arabia and 1 more
- Volunteers
- 200 people
- Sponsor
- Resverlogix Corp
COVID-19 Virus Infection, COVID-19
Evaluation of Clinical Performance and Usability of iStatis COVID-19 Ag Rapid Test at POC
A rapid point of care test for the detection of virus particles will be compared to the FDA approved EUA RT-PCR detection standard.
- Conditions
- COVID-19 Virus Infection, COVID-19, Coronavirus Disease-19, COVID-19 Pandemic
- Trial name
- NCT05514691
- Testing
- iStatis COVID-19 Ag Rapid Test, "COVID-19 RT-PCR Test EUA Number: EUA200011, Company: Laboratory Corporation of America ("Labcorp")
- Where
- 2 sites in United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- bioLytical Laboratories
COVID-19 Pneumonia
Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia
To study signals of efficacy and safety of a currently available dosage form (IM) of EG-009A in reducing the severity of respiratory disease in patients hospitalized with SARS-CoV-2 virus.
- Trial name
- NCT04561180
- Testing
- EG-009A, Standard of Care, Dexamethasone
- Sponsor
- Evergreen Therapeutics, Inc.
COVID-19
Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults
This is a phase 1 study to assess the safety and immunogenicity of different formulations of the investigational adjuvanted recombinant SARS-CoV-2 trimeric S-protein (from beta variant) subunit vaccine (SCB-2020S vaccine), when…
- Trial name
- NCT05228314
- Testing
- Candidate vaccine, SCB-2020S, Candidate vaccine, SCB-2019, Squalene based adjuvant
- Where
- 3 sites in South Africa
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
COVID-19 Pneumonia, COVID-19
Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and Above
This is a open label clinical trial to evaluate the efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines (Vero cell) in healthy people aged 3-17 years old in comparison with healthy population aged 18 years old…
- Trial name
- COVID-19 (NCT04917523)
- Testing
- SARS-CoV-2 Vaccine (Vero Cell), Inactivated
- Where
- United Arab Emirates
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
SARS-CoV-2, COVID-19
Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years
The purpose of this post-marketing study is to assess the safety of Comirnaty monovalent XBB.1.5. for booster vaccination children ages 6 months though 4 years under actual use medical practice.
- Trial name
- NCT06130410
- Testing
- COMIRNATY intramuscular injection
- Where
- Japan
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and Older
This Expanded Access, Phase 3, open label study is intended to provide access to COVAXIN™ (BBV152) to individuals who are at risk or have predisposing conditions that can lead to complications with the current immunization…
- Trial name
- NCT05541289
- Testing
- BBV152
- Where
- United States
- Sponsor
- Ocugen
SARS CoV 2 Infection
Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.
The objective of the study is to evaluate the efficacy and safety of two different doses of raloxifene orally administered compared to placebo in patients with early diagnosis of paucisymptomatic COVID-19.
- Trial name
- NCT05172050
- Testing
- Raloxifene
- Where
- 11 sites in France, Italy and 1 more
- Volunteers
- 61 people
- Sponsor
- Dompé Farmaceutici S.p.A
SARS-CoV-2
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
This study will evaluate 2 dose levels of mRNA-1283 in participants ≥6 months to <12 years to determine the optimal dose level per age group.
- Trial name
- NCT07808697
- Testing
- mRNA-1283, mRNA-1273
- Where
- 31 sites in United States, Argentina and 4 more
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19 Respiratory Infection, FLU
Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients
The primary objective of this study is to determine the safety and efficacy profile of the food supplement (KUNAMIN®) containing grape juice, seed, stem, and bark given to patients treated with the established treatment regimen…
- Conditions
- COVID-19 Respiratory Infection, FLU, Cold; Influenza, Bacterial Pneumonia
- Trial name
- NCT05417997
- Testing
- Kunamin®, Favipiravir, Enoxaparin
- Where
- Turkey (Türkiye)
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- RAAS Nutritionals, LLC
COVID, Drug Effect
Assessment of Mortality Rates in COVID-19 Infected Populations Treated With Repurposed Medications
This retrospective cohort study will include eligible patients that received a positive COVID-19 test and filled a new prescription for one of the repurposed medications (including hydroxychloroquine, chloroquine, with or without…
- Conditions
- COVID, Drug Effect, Drug Interaction, Risk Reduction
- Trial name
- NCT04432350
- Where
- United States
- Sponsor
- Tabula Rasa HealthCare
Covid19
Efficacy of Adaptogens in Patients With Long COVID-19
The aim of this clinical trial of a fixed combination of standardized extracts from Rhodiola rosea roots, Schisandra chinensis berry and Eleutherococcus senticosus root (ADAPT-232) in COVID-19 patients is to demonstrate possible…
- Trial name
- NCT04795557
- Testing
- ADAPT-232 oral solution
- Where
- Georgia
- Volunteers
- 100 people
- Sponsor
- Swedish Herbal Institute AB
COVID - 19
PA-001 Ph.1 Study in Healthy and Elderly Subjects
This was a double blind, randomized, placebo controlled, single and multiple IV dose study conducted in 2 parts, single ascending dose and multiple ascending doses parts.
- Trial name
- NCT07518771
- Testing
- PA-001
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- PeptiDream Inc.
COVID-19
A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection
This is a multicenter, open-label, controlled, randomized phase 2 study designed to evaluate the safety and efficacy profile of GNS561 in patients with COVID-19.
- Trial name
- CureCovid-2019 (NCT04637828)
- Testing
- GNS561
- Where
- France
- Volunteers
- 178 people
- Sponsor
- Genoscience Pharma